-
公开(公告)号：US10745490B2
公开(公告)日：2020-08-18
申请号：US15302342
申请日：2015-04-10
发明人： Joseph Schlessinger , Diego Alvarado , Sangwon Lee
IPC分类号： C07K16/32 , A61K39/395 , G01N33/74 , A61K39/00
摘要： Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB. Also provided are uses and methods for treating disorders, such as cancer, by administering to subject an antibody that binds to ErbB.
-
公开(公告)号：US11365228B2
公开(公告)日：2022-06-21
申请号：US16624895
申请日：2018-07-05
申请人： YALE UNIVERSITY
发明人： Joseph Schlessinger , Sangwon Lee
摘要： The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to β-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ ID NO:3 selected from the group consisting of V188, R203, and L194. In certain non-limiting embodiments, the construct further comprises a stability enhancing domain.
-
公开(公告)号：US20240083961A1
公开(公告)日：2024-03-14
申请号：US18176172
申请日：2023-02-28
申请人： YALE UNIVERSITY
发明人： Joseph Schlessinger , Sangwon Lee
IPC分类号： C07K14/50
摘要： The present invention relates in one aspect to the discovery that β-Klotho is the primary cell-surface receptor for FGF21, with FGFR1c functioning as a catalytic subunit that ultimately mediates intracellular signaling. In one aspect, the invention provides compositions and methods that are useful in treating or preventing endocrine FGF-related diseases or disorders.
-
公开(公告)号：US20200331978A1
公开(公告)日：2020-10-22
申请号：US16772100
申请日：2018-12-12
IPC分类号： C07K14/50
摘要： The present invention provides compositions and methods that are useful in treating or preventing endocrine FGF-related diseases or disorders, such as but not limited to dysfunctional phosphate homeostasis and chronic kidney disease (CKD).
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
